FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults
FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults Pharmaceutical Executive
September 2026
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer OncLive
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer
FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer ascopost.com
FDA Approves Etcamah Plus CDK4/6 Inhibitor for ESR1-Mutated Breast Cancer
FDA Approves Etcamah Plus CDK4/6 Inhibitor for ESR1-Mutated Breast Cancer Cure Today
FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer
FDA Approves Camizestrant for ESR1-Mutated HR+/HER2– Advanced Breast Cancer CancerNetwork